Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-β pathways.

Youn M, Huang H, Chen C, Kam S, Wilkes MC, Chae HD, Sridhar KJ, Greenberg PL, Glader B, Narla A, Lin S, Sakamoto KM.

Blood Adv. 2019 Sep 24;3(18):2751-2763. doi: 10.1182/bloodadvances.2019000537.

2.

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.

Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lübbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstöcker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM.

Haematologica. 2019 Oct;104(10):1935-1949. doi: 10.3324/haematol.2019.222059. Epub 2019 May 2.

3.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

4.

Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy.

Aleshin A, Greenberg PL.

Blood Adv. 2018 Oct 23;2(20):2787-2797. doi: 10.1182/bloodadvances.2018015834. Review.

5.

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS.

Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Santini V, Lübbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Leuk Res. 2018 Oct;73:51-57. doi: 10.1016/j.leukres.2018.08.022. Epub 2018 Sep 6.

6.

Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells.

Im H, Rao V, Sridhar K, Bentley J, Mishra T, Chen R, Hall J, Graber A, Zhang Y, Li X, Mias GI, Snyder MP, Greenberg PL.

Leuk Lymphoma. 2018 Dec;59(12):2952-2962. doi: 10.1080/10428194.2018.1452210. Epub 2018 Apr 4.

7.

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF.

J Hematol Oncol. 2017 Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2.

8.

Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729].

Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE.

Leuk Res. 2017 Aug;59:65. doi: 10.1016/j.leukres.2017.02.007. Epub 2017 May 30. No abstract available.

PMID:
28575698
9.

The classical nature of distinctive CMML monocytes.

Greenberg PL.

Blood. 2017 Mar 30;129(13):1745-1746. doi: 10.1182/blood-2017-02-767590. No abstract available.

PMID:
28360359
10.

The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders.

Bejar R, Greenberg PL.

J Natl Compr Canc Netw. 2017 Jan;15(1):131-135. No abstract available.

PMID:
28040723
11.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C.

J Natl Compr Canc Netw. 2017 Jan;15(1):60-87.

PMID:
28040720
12.

KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.

Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE.

Leuk Res. 2016 Nov;50:123-131. doi: 10.1016/j.leukres.2016.09.012. Epub 2016 Sep 28. Erratum in: Leuk Res. 2017 Aug;59:65.

PMID:
27736729
13.

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D.

Blood. 2016 Oct 20;128(16):2096-2097. doi: 10.1182/blood-2016-07-728766. Epub 2016 Aug 17. No abstract available.

14.

Time-dependent changes in mortality and transformation risk in MDS.

Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Levis A, Luebbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SM, Miyazaki Y, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Blood. 2016 Aug 18;128(7):902-10. doi: 10.1182/blood-2016-02-700054. Epub 2016 Jun 22.

15.

Immune checkpoint pathways: perspectives on myeloid malignancies.

Rivera GA, Saramipoor Behbahan I, Greenberg PL.

Leuk Lymphoma. 2016 May;57(5):995-1001. doi: 10.3109/10428194.2015.1107554. Epub 2016 Feb 25. Review.

PMID:
26916355
16.

Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.

Braulke F, Müller-Thomas C, Götze K, Platzbecker U, Germing U, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Hildebrandt B, Aul C, Stauder R, Valent P, Fonatsch C, Bacher U, Trümper L, Haase D, Schanz J.

Genes Chromosomes Cancer. 2015 Dec;54(12):809-17. doi: 10.1002/gcc.22292. Epub 2015 Sep 10.

PMID:
26355708
17.

Synergistic Interactions of Molecular and Clinical Advances for Characterizing the Myelodysplastic Syndromes.

Greenberg PL.

J Natl Compr Canc Netw. 2015 Jul;13(7):829-32. Review. No abstract available.

PMID:
26150576
18.

Myelodysplastic syndromes, version 2.2015.

Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 Mar;13(3):261-72.

19.

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).

Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M.

Leukemia. 2015 Jul;29(7):1502-13. doi: 10.1038/leu.2015.55. Epub 2015 Feb 27.

PMID:
25721895
20.

MDS prognostic scoring systems – past, present, and future.

Jonas BA, Greenberg PL.

Best Pract Res Clin Haematol. 2015 Mar;28(1):3-13. doi: 10.1016/j.beha.2014.11.001. Epub 2014 Nov 11. Review.

21.

Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival.

Johnson RC, Kurzer JH, Greenberg PL, Gratzinger D.

Am J Clin Pathol. 2014 Dec;142(6):795-802. doi: 10.1309/AJCP71OPHKOTLSUG.

PMID:
25389333
22.

Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.

Braulke F, Platzbecker U, Müller-Thomas C, Götze K, Germing U, Brümmendorf TH, Nolte F, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P, Fonatsch C, Trümper L, Haase D, Schanz J.

Haematologica. 2015 Feb;100(2):205-13. doi: 10.3324/haematol.2014.110452. Epub 2014 Oct 24.

23.

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q).

Sekeres MA, Swern AS, Fenaux P, Greenberg PL, Sanz GF, Bennett JM, Dreyfus F, List AF, Li JS, Sugrue MM.

Blood Cancer J. 2014 Aug 29;4:e242. doi: 10.1038/bcj.2014.62. No abstract available.

24.

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabrilove J, Erba HP, Gore SD, Tallman MS.

J Clin Oncol. 2014 Apr 20;32(12):1242-8. doi: 10.1200/JCO.2013.50.3102. Epub 2014 Mar 24.

25.

Update on Myelodysplastic Syndromes Classification and Prognosis.

Gratzinger D, Greenberg PL.

Surg Pathol Clin. 2013 Dec;6(4):693-728. doi: 10.1016/j.path.2013.08.005. Epub 2013 Oct 21.

PMID:
26839194
26.

Specific plasma autoantibody reactivity in myelodysplastic syndromes.

Mias GI, Chen R, Zhang Y, Sridhar K, Sharon D, Xiao L, Im H, Snyder MP, Greenberg PL.

Sci Rep. 2013 Nov 22;3:3311. doi: 10.1038/srep03311.

27.

The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features.

Greenberg PL.

J Natl Compr Canc Netw. 2013 Jul;11(7):877-84; quiz 885. Review.

PMID:
23847221
28.

Myelodysplastic syndromes: clinical practice guidelines in oncology.

Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M.

J Natl Compr Canc Netw. 2013 Jul;11(7):838-74.

29.

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.

Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, Fenaux P, Jadersten M, Hellstrom-Lindberg E, Gale RP, Beach CL, Lee SJ, Horowitz MM, Greenberg PL, Tallman MS, DiPersio JF, Bunjes D, Weisdorf DJ, Cutler C.

J Clin Oncol. 2013 Jul 20;31(21):2662-70. doi: 10.1200/JCO.2012.46.8652. Epub 2013 Jun 24.

30.

Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.

Pang WW, Pluvinage JV, Price EA, Sridhar K, Arber DA, Greenberg PL, Schrier SL, Park CY, Weissman IL.

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3011-6. doi: 10.1073/pnas.1222861110. Epub 2013 Feb 6.

31.

Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.

Koontz MZ, Horning SJ, Balise R, Greenberg PL, Rosenberg SA, Hoppe RT, Advani RH.

J Clin Oncol. 2013 Feb 10;31(5):592-8. doi: 10.1200/JCO.2012.44.5791. Epub 2013 Jan 7.

32.

Reduced rRNA expression and increased rDNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromes.

Raval A, Sridhar KJ, Patel S, Turnbull BB, Greenberg PL, Mitchell BS.

Blood. 2012 Dec 6;120(24):4812-8. doi: 10.1182/blood-2012-04-423111. Epub 2012 Oct 15.

33.

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J.

Leuk Lymphoma. 2013 Feb;54(2):321-8. doi: 10.3109/10428194.2012.713477. Epub 2012 Nov 15.

PMID:
22906162
34.

Revised international prognostic scoring system for myelodysplastic syndromes.

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D.

Blood. 2012 Sep 20;120(12):2454-65. Epub 2012 Jun 27.

35.

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.

Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U.

Blood. 2012 Aug 9;120(6):1290-8. doi: 10.1182/blood-2012-01-404699. Epub 2012 Jun 21.

36.

Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow.

Flores-Figueroa E, Varma S, Montgomery K, Greenberg PL, Gratzinger D.

Lab Invest. 2012 Sep;92(9):1330-41. doi: 10.1038/labinvest.2012.93. Epub 2012 Jun 18.

37.

Personal omics profiling reveals dynamic molecular and medical phenotypes.

Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Chen R, Miriami E, Karczewski KJ, Hariharan M, Dewey FE, Cheng Y, Clark MJ, Im H, Habegger L, Balasubramanian S, O'Huallachain M, Dudley JT, Hillenmeyer S, Haraksingh R, Sharon D, Euskirchen G, Lacroute P, Bettinger K, Boyle AP, Kasowski M, Grubert F, Seki S, Garcia M, Whirl-Carrillo M, Gallardo M, Blasco MA, Greenberg PL, Snyder P, Klein TE, Altman RB, Butte AJ, Ashley EA, Gerstein M, Nadeau KC, Tang H, Snyder M.

Cell. 2012 Mar 16;148(6):1293-307. doi: 10.1016/j.cell.2012.02.009.

38.

Molecular and genetic features of myelodysplastic syndromes.

Greenberg PL.

Int J Lab Hematol. 2012 Jun;34(3):215-22. doi: 10.1111/j.1751-553X.2011.01390.x. Epub 2011 Dec 27. Review.

PMID:
22212119
39.

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.

Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL.

Leuk Res. 2012 Jan;36(1):98-103. doi: 10.1016/j.leukres.2011.08.022. Epub 2011 Sep 14.

40.

Myelodysplastic syndromes: dissecting the heterogeneity.

Greenberg PL.

J Clin Oncol. 2011 May 20;29(15):1937-8. doi: 10.1200/JCO.2011.35.2211. Epub 2011 Apr 25. No abstract available.

PMID:
21519018
41.

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Jan;9(1):30-56.

42.

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.

Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP.

Blood. 2010 Oct 28;116(17):3163-70. doi: 10.1182/blood-2010-03-274753. Epub 2010 Jul 14.

43.

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

Greenberg PL, Koller CA, Cabantchik ZI, Warsi G, Glynos T, Paley C, Schiffer C.

Leuk Res. 2010 Dec;34(12):1560-5. doi: 10.1016/j.leukres.2010.06.013. Epub 2010 Jul 8.

PMID:
20615548
44.

Current therapeutic approaches for patients with myelodysplastic syndromes.

Greenberg PL.

Br J Haematol. 2010 Jul;150(2):131-43. doi: 10.1111/j.1365-2141.2010.08226.x. Epub 2010 May 5. Review.

PMID:
20507314
45.

NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes.

Greenberg PL, Rigsby CK, Stone RM, Deeg HJ, Gore SD, Millenson MM, Nimer SD, O'Donnell MR, Shami PJ, Kumar R.

J Natl Compr Canc Netw. 2009 Dec 29;7 Suppl 9:S1-16.

PMID:
20064286
46.

Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression.

Sridhar K, Ross DT, Tibshirani R, Butte AJ, Greenberg PL.

Blood. 2009 Nov 26;114(23):4847-58. doi: 10.1182/blood-2009-08-236422. Epub 2009 Oct 2.

47.

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, Paietta E, van der Jagt R, Houston J, Thomas ML, Cella D, Rowe JM.

Blood. 2009 Sep 17;114(12):2393-400. doi: 10.1182/blood-2009-03-211797. Epub 2009 Jun 29.

48.

A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes.

Gotlib J, Lavori P, Quesada S, Stein RS, Shahnia S, Greenberg PL.

Am J Hematol. 2009 Jan;84(1):15-20. doi: 10.1002/ajh.21316.

49.

The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.

Greenberg PL, Cosler LE, Ferro SA, Lyman GH.

J Natl Compr Canc Netw. 2008 Oct;6(9):942-53.

PMID:
18926103
50.

Myelodysplastic syndromes.

Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P; NCCN Myelodysplastic Syndromes Panel.

J Natl Compr Canc Netw. 2008 Oct;6(9):902-26. No abstract available.

PMID:
18926100

Supplemental Content

Loading ...
Support Center